Methods and compositions for the treatment of neurological diseases and disorders
First Claim
1. A method for preventing or treating a neurological disease in a mammalian subject comprising administering to the mammalian subject a compound capable of inhibiting prostaglandin E2 (PGE2) receptor, wherein the compound is administered in an amount effective to treat the neurological disease or to prevent its occurrence or recurrence.
1 Assignment
0 Petitions
Accused Products
Abstract
Methods and compositions are provided for preventing or treating neurodegenerative disease and other related diseases and disorders in a mammalian subject. The method provides administering to the mammalian subject a compound capable of inhibiting a PGE2 receptor, e.g., subtype EP2, wherein the compound is administered in an amount effective to treat the neurodegenerative disease or to prevent its occurrence or recurrence. A method for identifying compounds capable of inhibiting neurodegenerative disease is also provided.
-
Citations
28 Claims
- 1. A method for preventing or treating a neurological disease in a mammalian subject comprising administering to the mammalian subject a compound capable of inhibiting prostaglandin E2 (PGE2) receptor, wherein the compound is administered in an amount effective to treat the neurological disease or to prevent its occurrence or recurrence.
-
9. An in vitro method of screening for an inhibitor of PGE2 receptor biological activity comprising:
- contacting a cell with a test compound; and
detecting an increase or a decrease in activation, thereby identifying the test compound as an inhibitor of EP receptor biological activity. - View Dependent Claims (10, 11, 12)
- contacting a cell with a test compound; and
-
13. A method for identifying a compound capable of inhibiting PGE2 receptor signaling comprising:
-
contacting a test compound with a cell-based assay system comprising a cell expressing a PGE2 receptor capable of signaling responsiveness to PGE2 receptor signaling, and detecting an effect of the test compound on PGE2 receptor signaling in the assay system as an increase or a decrease in second messenger signaling or physiologic outcome such as increase or decrease in phagocytosis, effectiveness of the test compound in the assay being indicative of the inhibition EP receptor signaling. - View Dependent Claims (14, 15, 16, 17, 18, 19, 20, 21)
-
- 22. A pharmaceutical composition comprising an PGE2 inhibitor for the treatment of a neurological disease or disorder in a mammalian subject.
Specification